In addition, second‐line therapy with the anti‐PD‐1 mAb camrelizumab and the VEGFR‐2 TKI apatinib in patients with advanced nonsquamous NSCLC was associated with an ORR of 30.9% and a median PFS of 5.7 months.33 This evidence concerns the gene KDR and non-small cell lung carcinoma.